查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1993611

全球抗生物膜市场：按产品、分子、伤口类型、最终用户和地区划分－市场规模、产业趋势、机会分析和未来预测（2026-2035 年）

Global Anti-Biofilm Agents Market: By Product, Molecule, Wound Type, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 290 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球抗生物膜药物市场正快速扩张，反映出先进感染控制策略在医疗机构中日益增长的重要性。该市场在2025年的价值为18.4亿美元，预计未来十年将成长一倍以上，到2035年达到43.2亿美元。这一成长意味着2026年至2035年预测期间的复合年增长率（CAGR）为8.9%，显示市场对有效控制生物膜相关感染疾病的产品有着稳定且持续的需求。

抗菌素抗药性（AMR）日益严峻的挑战是推动市场强劲扩张的主要因素，而抗菌素抗药性已成为全球重大的健康问题。随着细菌对传统抗生素的抗药性不断增强，治疗和控制生物膜相关感染疾病的难度也随之增加。生物膜如同微生物群落的保护屏障，使其免受抗菌药物和宿主免疫反应的攻击，从而延长感染疾病，并增加根除难度。这种情况使得人们迫切需要能够破坏生物膜结构、增强抗菌药物疗效并最终改善患者预后的专用抗生物膜药物。

显着的市场趋势

现今的抗生物膜市场呈现出动态的格局，既有老牌化工企业和医疗集团，也有众多创新的中小型生技公司。这种格局造就了竞争激烈的市场环境，市场整合与分散并存，既促进了该领域的稳定发展，也推动了快速创新。大型跨国公司凭藉着雄厚的资源、成熟的生产能力和广泛的分销网络，保持着强大的市场地位。

主要企业包括3M、史密斯医疗、莫尔尼克医疗、康乐保、康维德、哈特曼集团Medtronic等全球知名公司。这些行业领导者凭藉数十年来提供的各种先进创伤护理和感染控制产品，建立了良好的声誉。他们丰富的产品系列涵盖敷料、凝胶、外用抗菌剂和具有抗生物膜特性的医疗设备，可满足医院和门诊环境中各种不同的临床需求。

同时，许多小规模生物技术公司的涌现也带来了新的创新和专业知识。这些公司通常专注于开发特异性生物膜相关感染疾病的新型分子、递送系统或诊断工具。他们的创新解决方案能够满足尚未满足的临床需求，并提供挑战传统方法的差异化产品。

主要成长要素

抗生物膜药物市场成长和创新的主要驱动力是日益严重的抗菌素抗药性（AMR）危机。到2025年，AMR已成为一项重大的全球健康威胁，与世界各地许多死亡病例直接相关。这一令人担忧的趋势凸显了开发有效策略和产品以对抗抗药性感染疾病（尤其是生物膜形成细菌引起的感染疾病）的紧迫性。生物膜是由微生物组成的复杂聚集体，包裹在保护性基质中，使细菌能够逃避传统的抗生素治疗，使感染疾病更持久且难以根除。

新机会的趋势

奈米技术在创伤护理的应用代表着一个充满前景且快速发展的新兴机会，预计将显着推动市场成长。奈米技术是指在分子或原子层面操控材料，进而开发出性能和功能更强大的创伤护理产品。这种尖端技术能够更精准地标靶化和控制治疗药物的释放，以传统创伤护理产品无法企及的方式提高治疗效果并加速癒合过程。

优化障碍

截至2025年，美国食品药物管理局（FDA）和环境保护署（EPA）等监管机构对产品必须正式标註为「抗生物膜」产品仍维持严格的要求。这些严格的标准旨在确保任何关于破坏或预防生物膜的说法都以可靠的科学证据为支撑，并透过标准化的测试通讯协定检验。由于生物膜是由微生物组成的复杂结构，其行为与空气传播的细菌不同，因此，证明其对生物膜的有效性需要比传统抗菌产品更专业、更具挑战性的测试方法。

目录

第一章执行摘要：全球抗生物膜市场

第二章：分析方法与框架

  • 分析目的
  • 产品概述
  • 市场区隔
  • 定性研究
    • 一手和二手资讯
  • 量化研究
    • 一手和二手资讯
  • 主要调查受访者组成：按地区划分
  • 本报告的前提条件
  • 市场规模估算
  • 数据检验

第三章：全球抗生物膜剂市场概览

  • 产业价值链分析
    • 原物料供应商
    • 製造商和製药公司
    • 销售代理商和服务供应商
    • 最终用户
  • 产业展望
    • 抗菌敷料的交易趋势
    • 主要买家和供应商
    • 抗生物膜技术的最新进展
    • 抗生物膜产品：研发管线概览
  • PESTLE分析
  • 波特五力分析
    • 供应商议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场成长及前景
    • 市场获利估算与预测（2020-2035）
    • 价格趋势分析

第四章：全球抗生物膜剂市场分析

  • 竞争格局概述
    • 市场集中度
    • 企业市场占有率分析（以金额为准，%）（2025 年）
    • 竞争对手分析与基准测试

第五章：全球抗生物膜剂市场分析

  • 市场动态和趋势
    • 成长要素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场规模及预测（2020-2035）
    • 副产品
    • 按分子
    • 按伤口类型
    • 最终用户
    • 按地区

第六章：北美市场分析

第七章：欧洲市场分析

第八章：亚太市场分析

第九章：中东和非洲市场分析

第十章：南美市场分析

第十一章：公司简介

  • Coloplast A/S
  • Convatec Inc.
  • Imbed Biosciences
  • Molnlycke AB
  • Smith+Nephew
  • Solventum
  • URGO MEDICAL
  • Other Prominent Players

第十二章附录

简介目录
Product Code: AA02261702

The global anti-biofilm agents market is experiencing rapid expansion, reflecting the growing importance of advanced infection control strategies in healthcare. Valued at USD 1.84 billion in 2025, the market is projected to more than double over the next decade, reaching an estimated valuation of USD 4.32 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 8.9% during the forecast period from 2026 to 2035, indicating steady and sustained demand for products that effectively combat biofilm-associated infections.

The driving force behind this robust market expansion is the escalating challenge posed by antimicrobial resistance (AMR), which has become a critical global health concern. As bacteria increasingly develop resistance to conventional antibiotics, infections associated with biofilms become harder to treat and control. Biofilms act as protective barriers that shield microbial communities from antimicrobial agents and the host immune response, making infections persistent and difficult to eradicate. This situation has created an urgent need for specialized anti-biofilm agents that can disrupt these structures, enhance antimicrobial efficacy, and ultimately improve patient outcomes.

Noteworthy Market Developments

The anti-biofilm agents market today is characterized by a dynamic mix of well-established chemical and healthcare conglomerates alongside a diverse array of smaller, innovative biotech companies. This blend creates a competitive landscape where market consolidation coexists with fragmentation, driving both stability and rapid innovation within the sector. Large multinational corporations bring extensive resources, established manufacturing capabilities, and broad distribution networks that enable them to maintain a strong foothold in the market.

Among the major players dominating the market are globally recognized companies such as 3M, Smith & Nephew, Molnlycke Health Care, Coloplast A/S, ConvaTec Inc., Hartmann Group, and Medtronic. These industry leaders have built their reputations over decades by supplying a wide range of advanced wound care and infection control products. Their extensive product portfolios often include dressings, gels, topical antimicrobials, and medical devices that incorporate anti-biofilm properties, catering to various clinical needs across hospital and outpatient settings.

At the same time, the presence of numerous smaller biotech firms introduces a layer of innovation and specialization. These companies often focus on developing novel molecules, delivery systems, or diagnostic tools specifically targeting biofilm-related infections. Their innovative solutions can address unmet clinical needs and offer differentiated products that challenge traditional approaches.

Core Growth Drivers

The primary catalyst driving growth and innovation in the anti-biofilm agents market continues to be the escalating Antimicrobial Resistance (AMR) crisis. As of 2025, AMR has emerged as a major global health threat, directly contributing to a significant number of deaths worldwide. This alarming trend has heightened the urgency to develop effective strategies and products that can combat resistant infections, particularly those involving biofilm-forming bacteria. Biofilms, which are complex communities of microorganisms encased in a protective matrix, enable bacteria to evade conventional antimicrobial treatments, making infections more persistent and difficult to eradicate.

Emerging Opportunity Trends

The adoption of nanotechnology in wound care represents a promising and rapidly emerging opportunity that could significantly drive growth within the market. Nanotechnology involves the manipulation of materials at the molecular or atomic level, enabling the development of wound care products with enhanced properties and functionalities. This cutting-edge approach allows for more precise targeting and controlled delivery of therapeutic agents, which can improve the effectiveness of treatments and accelerate the healing process in a way that traditional wound care products cannot match.

Barriers to Optimization

As of 2025, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) maintain stringent requirements for a product to be officially labeled as "Anti-Biofilm." These rigorous standards are designed to ensure that any claims related to biofilm disruption or prevention are supported by robust scientific evidence and validated through standardized testing protocols. Because biofilms are complex, structured communities of microorganisms that behave differently from free-floating bacteria, demonstrating efficacy against them requires specialized and often more challenging testing methods compared to those used for traditional antimicrobial products.

Detailed Market Segmentation

By Molecule, Silver-based solutions have consistently held the largest share in the anti-biofilm agents market due to their broad-spectrum antimicrobial properties and their widespread acceptance among clinicians for managing bioburden in high-risk or infected wounds. Silver's efficacy in targeting a wide range of microorganisms, including bacteria, fungi, and some viruses, makes it a reliable choice when topical antimicrobial action is critical to preventing infection and promoting wound healing. This broad coverage is especially important in clinical settings where wounds are prone to contamination or already infected, necessitating potent and dependable agents that can reduce microbial load and disrupt biofilm formation.

By Wound Type, chronic wounds represent the largest and most significant demand segment within the anti-biofilm agents market due to their high prevalence and the extended duration of treatment they typically require. Unlike acute wounds, which usually heal within a predictable timeframe, chronic wounds persist for weeks or months, creating an environment where biofilms are more likely to develop and complicate healing. The presence of biofilms in these wounds significantly increases the risk of infection and delays recovery, necessitating the use of specialized anti-biofilm agents to disrupt these bacterial communities and support effective treatment.

By End Users, hospitals stood out as the dominant end-users in the anti-biofilm agents market in 2025, reflecting their central role in managing the most critical and complex wound care cases. These facilities handle the highest-acuity wounds, including those that are severe, chronic, or slow to heal, which are particularly susceptible to biofilm-related infections. Additionally, hospitals perform the highest-risk surgeries where infection control is paramount, making the use of effective anti-biofilm agents essential to prevent complications and improve patient outcomes. Their established and standardized purchasing systems further facilitate the widespread adoption of these products on a large scale, enabling hospitals to procure and deploy the necessary wound care supplies.

By Product Type, dressings remain the top-performing product category in the anti-biofilm agents market due to their unique ability to deliver antibiofilm chemistry directly to the wound-exudate interface in a scalable and effective manner. These dressings are designed to maintain continuous contact with the wound environment, ensuring that the active agents consistently inhibit biofilm formation and promote healing. The direct application and sustained presence of these antimicrobial substances at the wound site make dressings particularly effective in managing chronic wounds, where biofilms pose a significant challenge to recovery.

Segment Breakdown

By Product

  • Dressings
  • Ointments / Gels
  • Powders

By Molecule

  • Silver
  • Iodine
  • Honey
  • Others

By Wound Type

  • Chronic Wounds
  • Acute Wounds

By End User

  • Hospitals
  • Wound Clinics
  • Home Care Settings
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America stands as the largest revenue contributor to the global anti-biofilm agents market, a position supported by several key factors that create a favorable environment for market growth. The region benefits from mature hospital systems known for their advanced infrastructure and high standards of patient care, which drive the adoption of innovative medical technologies. Additionally, the high per-patient healthcare spending in North America enables widespread access to premium treatments, including advanced wound-care products that incorporate anti-biofilm properties.
  • Recent market assessments estimate North America's share of the anti-biofilm agents market at approximately 36.95% in 2024, often rounded to about 37-38% in industry discussions. This substantial slice of the global market underscores North America's status as the focal point of current demand concentration. The region's dominance is not merely a result of economic factors but is also structurally linked to its clinical burden, particularly the high prevalence of chronic wounds.

Leading Market Participants

  • Coloplast A/S
  • Convatec Inc.
  • Imbed Biosciences
  • Molnlycke AB
  • Smith+Nephew
  • Solventum
  • URGO MEDICAL
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Anti-Biofilm Agents Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Anti-Biofilm Agents Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Manufacturers and Formulators
    • 3.1.3. Distributors and Service Providers
    • 3.1.4. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Trade Performance of Antimicrobial Dressings
    • 3.2.2. Major Buyers & Suppliers
    • 3.2.3. Recent Innovations in Anti-Biofilm Technology
    • 3.2.4. Pipeline Overview of Anti-Biofilm Products
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis

Chapter 4. Global Anti-Biofilm Agents Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Anti-Biofilm Agents Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Product Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Dressings
        • 5.2.1.1.2. Ointments / Gels
        • 5.2.1.1.3. Powders
    • 5.2.2. By Molecule
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Silver
        • 5.2.2.1.2. Iodine
        • 5.2.2.1.3. Honey
        • 5.2.2.1.4. Others
    • 5.2.3. By Wound Type
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Chronic Wounds
        • 5.2.3.1.2. Acute Wounds
    • 5.2.4. By End User
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Hospitals
        • 5.2.4.1.2. Wound Clinics
        • 5.2.4.1.3. Home Care Settings
        • 5.2.4.1.4. Others
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Product Type
      • 6.2.1.2. By Molecule
      • 6.2.1.3. By Wound Type
      • 6.2.1.4. By End User
      • 6.2.1.5. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Product Type
      • 7.2.1.2. By Molecule
      • 7.2.1.3. By Wound Type
      • 7.2.1.4. By End User
      • 7.2.1.5. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Product Type
      • 8.2.1.2. By Molecule
      • 8.2.1.3. By Wound Type
      • 8.2.1.4. By End User
      • 8.2.1.5. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Product Type
      • 9.2.1.2. By Molecule
      • 9.2.1.3. By Wound Type
      • 9.2.1.4. By End User
      • 9.2.1.5. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Product Type
      • 10.2.1.2. By Molecule
      • 10.2.1.3. By Wound Type
      • 10.2.1.4. By End User
      • 10.2.1.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Coloplast A/S
  • 11.2. Convatec Inc.
  • 11.3. Imbed Biosciences
  • 11.4. Molnlycke AB
  • 11.5. Smith+Nephew
  • 11.6. Solventum
  • 11.7. URGO MEDICAL
  • 11.8. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators